AB 343

Drug Profile

AB 343

Alternative Names: AB-343; nano-DAMIR

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator Aparna Biosciences
  • Class Antineoplastics; Gene therapies; MicroRNAs
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)
  • 21 Jul 2016 AB 343 is available for licensing as of 21 Jul 2016. http://www.aparnabio.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top